Literature DB >> 2591161

Absorption of ferric maltol, a novel ferric iron compound, in iron-deficient subjects.

S M Kelsey, D R Blake, R C Hider, C N Gutteridge, A C Newland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2591161     DOI： 10.1111/j.1365-2257.1989.tb00222.x

Source DB:  PubMed          Journal:  Clin Lab Haematol        ISSN： 0141-9854


× No keyword cloud information.
  5 in total

1.  Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency.

Authors:  Bernd Bokemeyer; Annette Krummenerl; Christian Maaser; Stefanie Howaldt; Michael Mroß; Nick Mallard
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

2.  Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program.

Authors:  Christoph Gasche; Tariq Ahmad; Zsolt Tulassay; Daniel C Baumgart; Bernd Bokemeyer; Carsten Büning; Stefanie Howaldt; Andreas Stallmach
Journal:  Inflamm Bowel Dis       Date:  2015-03       Impact factor: 5.325

3.  Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study.

Authors:  C Schmidt; T Ahmad; Z Tulassay; D C Baumgart; B Bokemeyer; S Howaldt; A Stallmach; C Büning
Journal:  Aliment Pharmacol Ther       Date:  2016-05-29       Impact factor: 8.171

4.  Oral iron supplementation with ferric maltol in patients with pulmonary hypertension.

Authors:  Karen M Olsson; Jan Fuge; Torben Brod; Jan C Kamp; Jan Schmitto; Tibor Kempf; Johann Bauersachs; Marius M Hoeper
Journal:  Eur Respir J       Date:  2020-11-12       Impact factor: 16.671

5.  Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.

Authors:  Stefanie Howaldt; Eugeni Domènech; Nicholas Martinez; Carsten Schmidt; Bernd Bokemeyer
Journal:  Inflamm Bowel Dis       Date:  2022-03-02       Impact factor: 5.325
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.